Clinique de sclérose en plaques et neuromusculaire de l'Outaouais Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2003
NCT00298662
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

interferon beta-1b (betaseron) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2